Camp4 Therapeutics gets UK approval for SYNGAP1 drug trial
Camp4 Therapeutics Corporation (Nasdaq: CAMP) has received authorization from the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA) to ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
